Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-55...

FDA Recall #D-0431-2017 — Class III — December 1, 2016

Recall #D-0431-2017 Date: December 1, 2016 Classification: Class III Status: Terminated

Product Description

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reason for Recall

Failed Dissolution Specifications

Recalling Firm

Teva Pharmaceuticals USA — North Wales, PA

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

6,800 cartons

Distribution

Nationwide in the USA and Puerto Rico

Code Information

Lot # 34027040A; Exp 10/17

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated